// App-Quantinova.ai

: Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia

Researchers

Presenter

  • William G. Wierda

Principal Investigators

  • Andrew W. Roberts

  • Paolo Ghia

  • Jennifer R. Brown

  • Stephan Stilgenbauer

  • Florence Cymbalista

  • Nicole Lamanna

  • John F. Seymour

  • Sebastian Bttcher

  • Madlaina Breuleux

  • Brenda Chyla

  • Lang Zhou

  • Jacqueline Nielsen

  • Su Young Kim

  • Jalaja Potluri

  • Johnathan C. Maher

  • Peter Hillmen

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

  • Walter and Eliza Hall Institute, Northcote, Australia

  • Universita Vita-Salute San Raffaele and IRCCS San Raffaele Scientific Institute, Milan, Italy

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Laboratoire -Hematologie Biologique, Hopital Avicenne, Bobigny, France

  • Hematology/Oncology Division, Columbia University Medical Center, New York, NY

  • Clinic III, Hematology, Oncology and Palliative Medicine, University of Rostock, Rostock, Germany

  • 2nd Department of Internal Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • AbbVie, Inc., North Chicago, IL

  • St. James's University Hospital, Leeds, United Kingdom

Locations

  • United States

  • Australia

  • Italy

  • Germany

  • France

  • Switzerland

  • United Kingdom

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02141282

  • NCT01889186

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved